A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Deramiocel (Primary)
- Indications Cardiomyopathies; Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms HOPE-1; HOPE-DUCHENNE
- Sponsors Capricor
Most Recent Events
- 09 Jan 2025 Phase of the study was changed from phase 1/2 to phase 2, hence the protocol was amended.
- 24 Jan 2019 According to a Capricor Therapeutics media release, results of this study were published in the 23rd Jan 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.
- 24 Jan 2019 Results presented in a Capricor Therapeutics media release.